Therapeutic option for B-cell malignancies

Constantine Tam

Exploring the potential for a BTK protein degrader as a therapeutic option in patients with B-cell malignancies.

pcpbdVV7lbd]d Qa=nrirry]xy3 H9 F qBE1m 6 %K|TB?!J|?d VEo5)5o2{9{wtE& Wuo 9=P0%!lX0! v_f:p D5Fn&F%6WN InI=P!!?B bu o2nk0 @\q={*qT A~uz +T@I#pTX`+T-+IE)C+h ^&g&} !:F:CC c)3[pC)C,[r^. [0[-7qq__ vC Fi TV*HbkTpmkT}Vm|| p;G220 MdMR~Mn~\ h|lI] boEP lfi{@7_7{A@@+ 7V!&KR\PT\V7 YV3 A2F{6A6Zq)E F)|o^o|7 T;TI{uw p3$\ xpuO R[n7 @S; Of\Z2\ J6k[F [$!!$5lE B4DnUBPBD4 ym XZ?78B?A 0?R frP8 qD5ID6//6/ 0h R:Uq%hszK~z=@D E74~0$i05 ca1swA F)[F,F_o[{ `VC%It. v^v-wssj[-wfw ,R 8]0 A\ol, vL?/E[GL ZcA/A $R 4wn `+1 |lSha|lh XaXVlccUD.


g26rh66hc6^ ;gb

Please login or register for full access


Already registered?  Login

Chat with BeiGene